NewsBenzingaVor Bio Announces Data Phase 3 Trial Of Telitacicept By Its RemeGen Partner Demonstrates Over 95% Participants Achieved At Least 5-Point MG-ADL Improvement Over 48 Weeks Vor Bio Announces Data Phase 3 Trial Of Telitacicept By Its RemeGen Partner Demonstrates Over 95% Participants Achieved At Least 5-Point MG-ADL Improvement Over 48 Weeks Benzinga 2026.09.29 12:07 (GMT+0) Open on Benzinga Other news Crypto market falls across the board, AI sector drops 5.09%, BTC briefly dips below $81,000 Elon Musk Hypes ‘Very Big Deal,’ but Cathie Wood Hits Sell on SpaceX Along With Meta, AMD and Google — Ark Loads Up on This Defense Stock Key News Last Night and This Morning (October 8–9) Tech stocks struggle on AI spending worries, elevated yields Oracle, Chipotle, Verizon, GameStop and Securitize Corp: Why These 5 Stocks Are on Investors' Radars Today US SOL spot ETFs see single-day net outflow of $3.3209 million
Elon Musk Hypes ‘Very Big Deal,’ but Cathie Wood Hits Sell on SpaceX Along With Meta, AMD and Google — Ark Loads Up on This Defense Stock
Oracle, Chipotle, Verizon, GameStop and Securitize Corp: Why These 5 Stocks Are on Investors' Radars Today
